Evidence map›Paper›PMID 29948043›Full record

ReviewWorld journal of urology2018

Molecularly-driven precision medicine for advanced bladder cancer.

Laura-Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, Shahrokh F Shariat, Kilian M Gust, Martin Boegemann

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Laura-Maria KrabbeDepartment of Urology, The University of Muenster Medical Center, Albert-Schweitzer, Campus 1, GB A1, 48149, Muenster, Germany. Lauramaria.Krabbe@ukmuenster.de.
Vitaly MargulisDepartment of Urology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Andres Jan SchraderDepartment of Urology, The University of Muenster Medical Center, Albert-Schweitzer, Campus 1, GB A1, 48149, Muenster, Germany.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Kilian M GustDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Martin BoegemannDepartment of Urology, The University of Muenster Medical Center, Albert-Schweitzer, Campus 1, GB A1, 48149, Muenster, Germany.
Medical University of Vienna · ATThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for clinicians and patients alike. However, for the most part of the last three decades, treatment and outcomes for patients with this disease have not changed a lot. With recent advances in immunooncology leading to the approval of multiple agents for the metastatic setting, the treatment landscape started to change. With the emergent data from landmark multi-institutional sequencing projects as well as molecular data from recent trials, our understanding of the underlying disease biology, response patterns as well as definition of molecular subtypes has evolved tremendously. This review aims to summarize the currently available concepts of mutational profiles and molecular subtypes as well as their implications for management of urothelial carcinoma.

Indexed as

Antibodies, MonoclonalCarcinoma, Transitional CellDisease-Free SurvivalFemaleHumansMaleMolecular Targeted TherapyNeoplasm InvasivenessNeoplasm StagingPrecision MedicinePrognosisRisk AssessmentSurvival AnalysisTreatment OutcomeUrinary Bladder NeoplasmsAntibodies, MonoclonalBladder cancerImmunotherapyMolecular profilesMolecular subtypesUrothelial carcinoma

Identifiers

PMID29948043
OpenAlexW2807627938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.